Who are AndroGel 1.62%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Talazoparib with enzalutamide, Winlevi, Nubeqa, Erleada, APALUTAMIDE, Aveed.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/androgel-1-62.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AndroGel 1.62% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AndroGel 1.62% (AndroGel 1.62%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen replacement therapy. Area: Endocrinology.

marketed Androgen replacement therapy Androgen receptor Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

AndroGel 1.62% (AndroGel 1.62%) — Repros Therapeutics Inc.. AndroGel 1.62% is a testosterone replacement therapy that restores physiological testosterone levels in hypogonadal men.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AndroGel 1.62% TARGET	AndroGel 1.62%	Repros Therapeutics Inc.	marketed	Androgen replacement therapy	Androgen receptor
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Nubeqa	darolutamide	Bayer	marketed		androgen receptor (AR)	2019-01-01
Erleada	apalutamide	Johnson & Johnson	marketed		Androgen receptor	2018-01-01
APALUTAMIDE	APALUTAMIDE		marketed		Androgen Receptor (AR)	2018-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen replacement therapy class)

Clarus Therapeutics, Inc. · 2 drugs in this class
Acerus Pharmaceuticals Corporation · 1 drug in this class
Acrux DDS Pty Ltd · 1 drug in this class
Alliance for Clinical Trials in Oncology · 1 drug in this class
Bayer · 1 drug in this class
Beersheva Mental Health Center · 1 drug in this class
Imperial College Healthcare NHS Trust · 1 drug in this class
Laboratoires Besins International · 1 drug in this class
Lipocine Inc. · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AndroGel 1.62% — Competitive Intelligence Brief. https://druglandscape.com/ci/androgel-1-62. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing